Market Segmentation:
- By Vaccine Type
- Inactivated
- Live Attenuated
- Recombinant
- Others
- By Technology
- Egg-based
- Cell-based
- Recombinant
- Others
- By Age Group
- Pediatric
- Adult
- By Distribution Channel
- Hospitals
- Clinics
- Pharmacies
- Others
- By Valence
- Trivalent
- Quadrivalent
- Other multivalent
- By Regions
- North America
- U.S.
- Canada
- Europe
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Latin America
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Middle East & Africa
- GCC Countries
- Israel
- South Africa
- North Africa
- Central Africa
- Rest of the Middle East
Frequently Asked Questions
The current market size of the seasonal influenza industry is around $6.5 billion in 2023.
Rising disease burden and influenza pandemics threats, Advances in cell-based and recombinant vaccine technologies, Use of adjuvants and high-dose vaccines for better efficacy, Introduction of quadrivalent and higher valency vaccines, Growing demand from emerging markets, Increased recommendation of flu vaccines for broader populations
Inactivated vaccines segment.
The market is expected to grow at a CAGR of 5.5% from 2023 to 2031, reaching $10.0 billion by 2031.
Rising disease burden of influenza, Need for improved vaccines with broader, longer-lasting protection, Advances in cell-based and recombinant vaccine technologies, Use of adjuvants and high-dose vaccines for better efficacy, Introduction of quadrivalent and higher valency vaccines